Gilead Furnishes Biktarvy Patent Litigation Settlement Details
Summary
On October 6, 2025, Gilead Sciences, Inc. ("Gilead") announced it entered into settlement agreements to resolve patent litigations with generic manufacturers Lupin Ltd., Cipla Ltd., and Laurus Labs Ltd. These agreements concern generic versions of Biktarvy®. As a result, no generic entry for Biktarvy tablets is expected in the United States prior to April 1, 2036.
Why It Matters
This settlement extends the market exclusivity for Biktarvy, a key product, until April 1, 2036, in the U.S., which is significant for Gilead's future revenue streams and intellectual property protection.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how GILD traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View GILD Charts on TradingViewAffiliate link
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000882095
- Filing Date
- Monday, October 6, 2025
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- neutral